Latest news and press releases about Candel Therapeutics, Inc. (CADL): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical firm based in Needham, Massachusetts, dedicated to developing innovative immunotherapies for cancer patients. Its pipeline features CAN-2409, which is presently in Phase II clinical trials for pancreatic and lung cancers, and has progressed to Phase III for prostate cancer. This therapy also successfully completed Phase Ib/II trials for high-grade glioma.
Price
| Price | $11.02 |
| Market Cap | $807M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 5.42 |
| EV / EBITDA | -7.48 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -89.38% |
| Return on Invested Capital | -36.74% |
| Return on Assets | -42.53% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ALDX · CABA · CAPR · CTNM · EDIT · GNLX · IMMP
Explore sector: Healthcare · Biotechnology
More sections of CADL: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks